文献速递免疫规划传染病防控与疫情报告

九州2021年1月至9月因类COVID-19疾病住院成人中实验室确诊COVID-19:感染诱导免疫与mRNA疫苗诱导免疫的比较

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-11-05

CDC利用VISION网络数据,比较既往感染未接种者与全程接种mRNA疫苗无感染史者因类COVID-19疾病住院时实验室确诊COVID-19的 odds。在既往感染或接种发生在90-179天前的人群中,未接种既往感染者的调整比值比(aOR)为5.49(95%CI 2.75-10.99),高于全程接种mRNA疫苗者。提示疫苗诱导免疫对实验室确诊COVID-19的保护优于感染诱导免疫,所有符合条件者应尽快接种疫苗。

要点

  • 既往感染未接种者因类COVID-19疾病住院时实验室确诊COVID-19的 odds 高于全程接种mRNA疫苗者(aOR=5.49;95%CI 2.75-10.99)。
  • 分析纳入≥18岁、2021年1月至9月因类COVID-19疾病住院且至少检测两次的成人。
  • 所有符合条件者应尽快接种COVID-19疫苗,包括既往感染未接种者。

核心结论

  • 在既往感染或接种发生在90-179天前的类COVID-19疾病住院成人中,疫苗诱导免疫对实验室确诊COVID-19的保护优于感染诱导免疫。
  • 所有符合条件者应尽快接种COVID-19疫苗,包括既往感染SARS-CoV-2的未接种者。

研究设计与样本

  • CDC利用VISION网络数据,纳入≥18岁、2021年1月至9月因类COVID-19疾病住院且至少检测两次的成人。
  • 比较既往感染90-179天前未接种者与全程接种mRNA COVID-19疫苗90-179天前且无既往感染记录者实验室确诊COVID-19的 odds。
  • 分析调整社会人口学和健康特征。

主要发现

  • 既往感染或接种发生在90-179天前的人群中,未接种既往感染成人实验室确诊COVID-19的调整比值比高于全程接种mRNA疫苗且无既往感染记录者(aOR=5.49;95%CI=2.75-10.99)。

临床怎么用

  • 所有符合条件者应尽快接种COVID-19疫苗,包括既往感染SARS-CoV-2的未接种者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous infection with SARS-CoV-2 (the virus that causes COVID-19) or COVID-19 vaccination can provide immunity and protection from subsequent SARS-CoV-2 infection and illness. CDC used data from the VISION Network* to examine hospitalizations in adults with COVID-19-like illness and compared the odds of receiving a positive SARS-CoV-2 test result, and thus having laboratory-confirmed COVID-19, between unvaccinated patients with a previous SARS-CoV-2 infection occurring 90-179 days before COVID-19-like illness hospitalization, and patients who were fully vaccinated with an mRNA COVID-19 vaccine 90-179 days before hospitalization with no previous documented SARS-CoV-2 infection. Hospitalized adults aged ≥18 years with COVID-19-like illness were included if they had received testing at least twice: once associated with a COVID-19-like illness hospitalization during January-September 2021 and at least once earlier (since February 1, 2020, and ≥14 days before that hospitalization). Among COVID-19-like illness hospitalizations in persons whose previous infection or vaccination occurred 90-179 days earlier, the odds of laboratory-confirmed COVID-19 (adjusted for sociodemographic and health characteristics) among unvaccinated, previously infected adults were higher than the odds among fully vaccinated recipients of an mRNA COVID-19 vaccine with no previous documented infection (adjusted odds ratio [aOR] = 5.49; 95% confidence interval [CI] = 2.75-10.99). These findings suggest that among hospitalized adults with COVID-19-like illness whose previous infection or vaccination occurred 90-179 days earlier, vaccine-induced immunity was more protective than infection-induced immunity against laboratory-confirmed COVID-19. All eligible persons should be vaccinated against COVID-19 as soon as possible, including unvaccinated persons previously infected with SARS-CoV-2.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Bozio CH, Grannis SJ, Naleway AL, et al. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34735425. doi:10.15585/mmwr.mm7044e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。